论文部分内容阅读
目的 :探究在晚期非小细胞肺癌的临床治疗中多西他赛单药和多西他赛联合顺铂二线治疗效果分布情况。方法 :选取2014年6月至2015年6月在我院治疗的晚期非小细胞肺癌患者120例作为研究对象,随机分为对照组和观察组各60例,对照组患者采用多西他赛进行治疗,观察组患者则在对照组治疗的基础上采用顺铂进行联合治疗,对比两组患者的临床治疗效果以及其不良反应发生情况。结果 :观察组临床治疗总有效率明显高于对照组,差异显著具有统计意义(P<0.05),同时观察组患者的不良反应发生率明显低于对照组,差异显著具有统计意义(P<0.05)。结论 :在晚期非小细胞肺癌患者的临床治疗中应用多西他赛联合顺铂二线进行治疗效果优于多西他赛药物单用治疗,同时对副作用有一定的缓解作用,值得在临床上推广应用。
Objective: To investigate the effect of docetaxel monotherapy and docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods: A total of 120 patients with advanced non-small cell lung cancer who were treated in our hospital from June 2014 to June 2015 were selected as study subjects and randomly divided into control group and observation group of 60 cases each. Patients in the control group were treated with docetaxel Treatment, observation group patients in the control group based on the use of cisplatin combination therapy, compared the two groups of patients with clinical effects and adverse reactions. Results: The total effective rate of clinical observation in observation group was significantly higher than that in control group (P <0.05), and the incidence of adverse reactions in observation group was significantly lower than that in control group (P <0.05 ). Conclusions: The combination of docetaxel and cisplatin in the treatment of patients with advanced non-small cell lung cancer is superior to docetaxel alone in the treatment of patients with advanced non-small cell lung cancer. Meanwhile, it has a certain relieving effect on the side effects and is worthy of clinical promotion application.